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Abstract
Background and Aims: The association between hygiene and prevalence of autoimmune disease has been attributed in
part to enteric helminth infection. A pilot study of experimental infection with the hookworm Necator americanus was
undertaken among a group of otherwise healthy people with celiac disease to test the potential of the helminth to suppress
the immunopathology induced by gluten.
Methods: In a 21-week, double-blinded, placebo-controlled study, we explored the effects of N. americanus infection in 20
healthy, helminth-naı¨ve adults with celiac disease well controlled by diet. Staged cutaneous inoculations with 10 and 5
infective 3rd stage hookworm larvae or placebo were performed at week-0 and -12 respectively. At week-20, a five day oral
wheat challenge equivalent to 16 grams of gluten per day was undertaken. Primary outcomes included duodenal Marsh
score and quantification of the immunodominant a-gliadin peptide (QE65)-specific systemic interferon-c-producing cells by
ELISpot pre- and post-wheat challenge.
Results: Enteric colonisation with hookworm established in all 10 cases, resulting in transiently painful enteritis in 5. Chronic
infection was asymptomatic, with no effect on hemoglobin levels. Although some duodenal eosinophilia was apparent,
hookworm-infected mucosa retained a healthy appearance. In both groups, wheat challenge caused deterioration in both
primary and several secondary outcomes.
Conclusions: Experimental N. americanus infection proved to be safe and enabled testing its effect on a range of measures
of the human autoimmune response. Infection imposed no obvious benefit on pathology.
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Introduction
The ‘‘hygiene hypothesis’’ proposes that the increasing
prevalence of allergic and autoimmune diseases in developed
countries may be due to the reduction in the incidence of
infectious diseases [1]; epidemiologic and genetic studies suggest
that the decline in the prevalence of helminth infections is a major
factor [2–5]. Observational studies supporting this hypothesis
include a report that infection with the nematode Strongyloides
stercoralis is associated with protection against autoimmune liver
disease [6], and another showing that unspecified helminth
infections with peripheral eosinophilia are associated with reduced
autoantigen-specific responses and disease progression in multiple
sclerosis [7]. Co-infection with helminths is also known to
attenuate murine models of autoimmunity and inflammatory
bowel disease [8,9].
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Despite being classed as pathogens [10], helminth parasites are
being proposed as treatments for allergic and autoimmune diseases
[11,12]. Preliminary observations suggest that intentional infection
with the zoophilic Trichuris suis is safe [13], and reduces the activity
of inflammatory bowel disease [13,14]. However, dosing with T.
suis every three weeks is required to maintain ongoing infection
because the human host does not sustain development of T. suis to
maturity [14].
Necator americanus (NA) is a long-lived hematophagous, human-
specific (anthropophilic) gastrointestinal nematode that infects over
500 million people in developing countries where heavy infection
causes iron deficiency anemia, and is associated with reduced
physical and intellectual development [15]. Experimental infection
of healthy volunteers with NA infective third-stage larvae (L3) may
cause an acute, painful enteropathy [16–18]. Recent published
data indicate that low-dose inocula of NA are better tolerated [19],
and because they do not proliferate in humans, a defined dose can
be administered and later fully eliminated with anthelmintic
therapy [19]. A further advantage is infected individuals pose no
risk to others because hookworms are soil-transmitted (geohel-
minths) and cannot be propagated in modern sanitary environ-
ments.
We chose NA and celiac disease (CD) to explore the relationship
between helminth infection and intestinal inflammation due to a
well characterised dietary antigen, gluten. Our previous studies
with this hookworm have provided us with a pure source of
infective larvae [18,20]. Individuals carrying chronic infection with
hookworms in endemic settings demonstrate parasite-specific TH2
responses, but TH1 and TH2 immune responses to other antigens
are diminished [21].
Celiac disease is uniquely suited to explore the effects of
helminth infection; it is common [22] and remission is achieved
with elimination of dietary gluten allowing host-parasite interac-
tion to be studied free of potential artefacts caused by medications.
Clinical studies in volunteers with CD also have the advantage that
the effects of deliberate gluten exposure can be measured by
symptom response, in blood and intestinal tissue [23–26]. Over
90% of people with CD possess genes encoding the major
histocompatability (MHC) Class II molecule, HLA-DQ2, and
HLA DQ2-restricted CD4+ T cells specific for deamidated gluten
peptides can be isolated from intestinal tissue [26]. HLA DQ2-
restricted CD4+ TH1 cells specific for deamidated gluten including
the immunodominant a-gliadin 17-mer p57-73 (QE65) peptide
are also present in blood after oral wheat challenge [27].
In this study, we undertook a clinical trial to test whether NA
infection reduces the immunotoxic effects of gluten in CD.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
The Princess Alexandra Hospital, Queensland Institute of
Medical Research and Townsville Hospital Human Research
Ethics Committees approved the study. Written informed consent
was obtained from all subjects.
Patients
Healthy people with CD aged 18 years or older were invited to
participate through the Queensland Coeliac Society. Inclusion
criteria included: 1) pre-treatment histological diagnosis of Marsh
grade 3 celiac disease [25], 2) positive immunoglobulin (Ig) A anti-
tissue transglutaminase (tTG) or anti-endomysial antibody, 3)
HLA-DQ2 phenotype, and 4) adherence to a gluten-free diet
(GFD) for at least 6 months pre-enrolment [28]. Subjects were
excluded if they had 1) insulin dependent diabetes mellitus or
Addison’s disease; 2) life threatening allergy; 3) treatment with
immunomodulatory therapies within the six months prior to
enrolment (including aspirin, non-steroidal anti-inflammatory
drugs, celocoxib inhibitors, statins or intramuscular and intrave-
nous steroids); 4) an unmanaged risk of pregnancy; 5) historical,
fecal or serological evidence of a prior helminth infection; 6) iron
deficiency anemia, 7) any vaccination within the 30-day period
prior to study commencement, or 8) an elevated level of tTG IgA.
Study Design
This was a prospective, randomized, double-blinded, placebo-
controlled trial evaluating the safety, tolerability and immunolog-
ical effects of NA infection in subjects with CD in remission on
gluten free diet and during wheat challenge. Participants were
matched by age and gender (Table 1). Using a random number
generation sequence, the researcher preparing inocula indepen-
dently of the clinical support, assigned participants to the
‘‘hookworm’’ and ‘‘control’’ groups. Primary end-points included
duodenal histology Marsh scores and systemic interferon-c
measured by QE65-ELISpot pre- and post-wheat challenge.
Secondary end-points included a) the clinical response to
inoculation with hookworm, and b) subsequent response to the
in vivo wheat challenge, as measured by symptom and laboratory
indices, intraepithelial duodenal CD4+, CD8+ and CD3+ lympho-
cyte counts (IEL), and duodenal villus height/crypt depth (Vh/Cd)
ratios. Because this was a Phase 1b/2a clinical trial assessing
Table 1. Participant demographics.
Control Subjects (n=10) Hookworm Subjects (n =10)
Age (years)1,2 44 (25–58) 47 (25–62)
Gender (M/F) 2/8 2/8
BMI (kg/m2)3,2 27 (22–32) 26 (18–31)
IgA tTG3 (U/ml)4,2 9 (5–15) 8 (5–19)
Duration (months)5,2 70 (10–325) 77 (15–143
1Age at enrolment,
2mean value (range),
3Body Mass Index,
4Pre-enrolment IgA anti-tissue transglutaminase (normal range below 20 U/ml),
5duration of gluten free diet.
doi:10.1371/journal.pone.0017366.t001
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safety, the hookworm and control sample sizes were deliberately
limited to ten volunteers each. Subjects and investigators remained
blinded throughout the trial.
Inocula and inoculation. Inoculations were performed at
wk 0 (either 10 L3 or placebo) and wk 12 (either 5 L3 or placebo).
Inocula of five or ten NA L3 were prepared as previously described
[18]. Placebo consisted of an identically presented inoculum
containing 0.2 ml McIlhenny Co Tabasco Pepper SauceH to
mimic the pruritus that accompanies skin penetration by L3. A
control sample of L3 was submitted with every batch of inoculum
including placebo, and was inspected microscopically for larval
motility to verify viability. All vials and pipettes were examined
following inoculation to ensure that there were no residual
hookworm larvae. Evidence of hookworm infection was
provided by peripheral blood eosinophil count (6109/L), and
documenting hookworm eggs in feces by microscopy and/or by
sighting a hookworm at endoscopy.
A strict GFD was maintained from weeks 0 to 20. Endoscopy
was performed at week 20 using an Olympus high resolution
digital endoscope; five single-bite biopsies were collected from the
third part of the duodenum (D3), and seven from the second part
(D2). Volunteers consumed two 50 g slices of white bread twice a
day (equivalent to 16 g of gluten daily) for five days. On the sixth
day, blood was collected and a second endoscopy was performed
(referred to as the week 21 timepoint).
Monitoring, assessments and wheat challenge. Clinical
reviews occurred at weeks 0, 4, 12, 20 and 21, and symptom
diaries were recorded weekly. From weeks 0–20 and daily during
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0017366.g001
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the wheat challenge, participants were asked to complete a
symptom score rating from 0 (none) to 3 (severe) bloating,
constipation, flatulence, headaches, lethargy, mouth ulcers,
nausea, skin rash, skin itch, and vomiting, and to record their
number of bowel motions, loose bowel motions and urgent bowel
motions, and the number of episodes of pain per day. Also
recorded were pain intensity and general wellbeing on a visual
analogue scale from ‘‘no pain at all’’ to ‘‘very severe’’ and ‘‘very
well’’ to ‘‘severely ill’’ respectively.
Histopathological Analysis
Biopsies were fixed in neutral buffered formalin, processed and
carefully orientated and embedded in paraffin wax. Sections (3 mm)
were stained with hematoxylin and eosin (H&E) and immunostained
with anti-CD8, anti-CD4 and anti-CD3 antibodies (all from
Novocastra Laboratories Ltd). The Marsh scores were graded by
two independent researchers [25]. The IELs per 100 nucleated
enterocytes (100NE) were counted at 24 randomly selected sites
between the villus tip to the base of the crypt in each biopsy. The Vh/
Cd ratios were measured independently of the Marsh grading [24]
and were performed on 10 randomly selected well-orientated sites.
Peripheral blood interferon-c ELISpot responses to the
immunodominant a-gliadin peptide p57–73 QE65
Peripheral blood mononuclear cells (PBMCs) were incubated
with p57–73 QE65 (50 mg/ml) in overnight IFN-c ELISpot assays,
as previously described [27]. Briefly, ELISpot plates were coated
with anti-IFN-c (clone 1-D1K, Mabtech) and then blocked with
5% fetal calf serum (FCS). Freshly isolated PBMCs were added to
wells containing medium alone (RPMI 1640, Invitrogen, 10% fetal
bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and
2 mM L-glutamine) or p57–73 QE65 in medium, and cultured for
24 h at 37uC in 5% CO2. Cells were removed and the plates were
incubated with anti-IFN-c-biotin (clone 7-B6-1, Mabtech), then
streptavidin-alkaline phosphatase, and developed with BCIP/NBT
substrate. Spots were counted on an iSpot ELISpot reader
(Autoimmun Diagnostika GmbH).
Statistical Analyses
Statistical analyses were performed using Prism5 (GraphPad).
When comparing non-continuous variables (eg. symptom scores),
area under the curve analysis from week 1 to week 20 followed by
Mann-Whitney U test was used to compare between groups. For
continuous variables (eg. duodenal IEL counts), two-way ANOVA
was used to analyse between time-points and groups. In the
figures, * = p,0.05, ** = p,0.01, *** = p,0.001.
Results
Between October 2007 and March 2008, 131 potential subjects
indicated interest, 61 were screened and twenty were enrolled and
completed the study without protocol violations (Figure 1).
Reasons for exclusion of subjects are summarised in Figure 2.
Figure 2. Recruitment and Protocol. Recruitment and summation of those excluded post screening (A), and trial outline (B).
doi:10.1371/journal.pone.0017366.g002
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Hookworm Tolerance and Safety
Inoculation efficacy. Mature hookworm infection was
confirmed in each of the hookworm group by the identification
of eggs in feces (n = 5), or by endoscopic visualisation of at least
one adult worm (n= 8; Figure 3A), or by both (n = 3). In five
subjects with proven infection, patency could not be confirmed by
fecal microscopy despite the testing of 17 of 18 scheduled
collections from wk 12–21. No control subject had evidence of
hookworm infection and no subject had evidence of any other
helminth infection.
Clinical response to N. americanus. Symptom scores: No
serious adverse event relating to hookworm infection occurred. All
subjects in the hookworm group developed multiple tiny papules
shortly after the application of L3 (Figure 3B). Symptoms were
scored by questionnaire over the 20 weeks of hookworm infection
(Figure 4A–F). The hookworm group experienced pain during the
initial colonisation of the intestine, but this resolved completely by
week 16 (Figure 4A). There were trends towards the hookworm
group having less frequent bowel actions after colonisation was
established (Figure 4B), and more flatulence (4C), nausea and
bloating (data not shown) at earlier timepoints. The inoculation
site remained itchy until week 4 (Figure 4D). Unexpectedly, the
hookworm group experienced less lethargy than the controls
(Figure 4E), and wellbeing was unaffected (Figure 4F). At week 21,
5 of 10 subjects in the control group incorrectly guessed that they
were in the active hookworm-infected group, while 8 of the 10 in
Figure 4. Symptom responses to hookworm infection. Control group is indicated by black circles, hookworm group by grey squares, values
are mean +/2 SEM. (A) pain events, (B) bowel motions/day, (C) flatulence, (D) skin rash, (E) lethargy, (F) wellbeing. Area under the curve analysis
followed by Mann-Whitney U test to compare between groups showed that pain events (A) was significantly different between the groups.
doi:10.1371/journal.pone.0017366.g004
Figure 3. Representative photographs of parasitic infection (A) Adult hookworm (B) Inoculation site.
doi:10.1371/journal.pone.0017366.g003
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the hookworm group confidently and correctly identified his or her
infection status. At the end of the study all infected subjects were
offered anthelminthic treatment but declined.
Laboratory Indices: A modest leukocytosis with an eosinophilia was
noticeable from week 4 after hookworm inoculation (Figure 5A–
B). Hemoglobin levels were stable from week 0 to 20, but dropped
at week 21 in both groups after wheat challenge (Figure 5C).
Oral wheat challenge
Primary outcomes. Mucosal damage measured by Marsh score: In
both the hookworm and control groups, mucosal damage
deteriorated after the 5-day wheat challenge (Figure 6A).
Although this deterioration was pronounced in the control group
(p = 0.02), there was no statistical difference in Marsh score
between hookworm and control groups.
Systemic inflammatory immune responses: Gluten-specific IFN-c-
producing PBMCs were measured by ELISpot before and after
wheat challenge (Figure 6B). As expected, T cells secreting IFN-c
in response to p57–73 QE65 were absent prior to wheat challenge
(data not shown), but were mobilised into blood following the
challenge. The frequency of IFN-c secreting T cells specific for
p57–73 QE65 increased significantly only in the control group
(p = 0.01), but the difference between the groups was not
significant.
Secondary Outcomes. Clinical response to wheat challenge —
Symptom scores: Nine subjects (4 with hookworm and 5 controls)
developed abdominal discomfort, bloating and vomiting 1–
2 hours after the oral wheat challenge. These symptoms resolved
within 2–4 hours (data not shown). These symptoms did not recur
despite continuation and completion of the five day wheat
challenge. There was no significant difference between the
groups during week 20 in level of pain intensity or episodes of
pain, number or urgency of bowel motions, vomiting, nausea
bloating, headaches, lethargy or well-being.
Mucosal inflammatory response — Duodenal histological measurements:
After the 5-day in vivo wheat challenge, the total, CD3+ and CD8+
duodenal IEL counts increased in both groups (Table 2). The
CD4+ IEL counts were not significantly affected by either in vivo
wheat challenge or hookworm infection. A robust but almost
identical decrease in the Vh:Cd ratio after gluten was measured in
the hookworm and control groups (Table 2).
Discussion
The ‘‘hygiene hypothesis’’ is a plausible explanation for the
increasing incidence of autoimmune and allergic diseases in
affluent societies, but it has been difficult to directly elucidate the
mechanism by which infectious agents such as nematodes alter
disease-causing immune responses in humans. In common with
many other immune diseases, the prevalence of CD has risen
dramatically. We propose that chronic helminthiasis, such as
hookworm infection, may be immunomodulatory and alter
pathogenic immune responses in vivo.
In this Phase 1b/2a trial, we have established an experimental
model allowing us to explore how hookworm infection alters the
effects of gluten in CD. Chronic hookworm infection can be
reliably and safely established in subjects with well controlled
disease. Lacking precedent, the size of this demanding study was
small. We observed at best weak trends towards reduced numbers
of gluten peptide-specific T cells in blood and histological damage
following wheat challenge in CD.
As has been reported in another trial, standard fecal microscopy
is relatively insensitive in light infection; a negative test does not
exclude colonization [29]. All patients inoculated acquired adult
hookworms in the intestine. The pathognomic findings of a
transient papular rash at the site of inoculation, together with the
common development of mild abdominal pain in the period soon
after the initial inoculation hampered attempts to blind the
hookworm-infected participants and investigators. In each control
participant however, genuine confusion as to status was usual. It is
inherently difficult to mask the hallmark features of hookworm
inoculation, just as it is to mimic them. Rather than inoculating
every participant and subsequently treating the controls with an
Figure 5. Blood cell and marker levels. (A) white cell, (B) eosinophil
(C) hemoglobin. Control group is indicated by black circles, hookworm
group by grey squares, values are mean +/2 SEM. Data was analyzed by
two-way ANOVA: significant effects of time and interaction was shown
in (B), and post-hoc one-way ANOVA on each group showed the
differences between timepoints as indicated.
doi:10.1371/journal.pone.0017366.g005
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anthelminthic, we felt obliged to accept this compromise. The
occurrence of abdominal pain has implications when evaluating
hookworms as therapy in clinical trials, especially during the
establishment phase where symptom scores to measure outcomes
may be confounded [20]. Because infection with NA typically
persists for years [30,31], the morbidity occurring during early
infection should be accounted for by undertaking studies after
chronic infection is established.
The refusal of all participants in the active arm to take
anthelminthic therapy after completion of the trial was not unique
to this study [20,32] and supports the contention that chronic light
hookworm infection does not compromise wellbeing, an argument
congruous with the trend in the improved lethargy score. Although
it is well recognized that heavy hookworm infection causes
clinically significant blood loss [15], the legitimate concern that
experimental infection would cause anemia in patients already
predisposed with CD did not eventuate. As anticipated from a
previous experimental inoculation study utilising capsule endos-
copy [18], the hookworm group acquired peripheral and mucosal
eosinophilia but the mucosa at week 20 was not obviously
damaged.
Following the epidemiological evidence of a causal association
between the disappearance of helminths from societies with
advanced sanitary infrastructure and the apparent rise in incidence
of autoimmune and allergic diseases [3], a number of interven-
tional clinical trials have been undertaken [12,20,32,33], with
inconsistent results. The porcine whipworm, T. suis, has been
reported as beneficial in Crohn’s disease and ulcerative colitis [33],
both conditions which share genetic traits with CD [34]. However,
a recently reported controlled trial using this helminth in patients
with allergic rhinitis demonstrated that while an immunological
response to whipworm was elicited, no therapeutic benefit was
apparent [12]. Similarly, in a trial where NA infection was tested
for an effect among patients with asthma, no significant benefit
from helminth infection was reported [32]. While our experience
from a proof of concept study where patients with active Crohn’s
disease were infected with hookworm suggested an early benefit,
their wellbeing was reliant on continuation of immunosuppressive
therapies [20].
Our study establishes that hookworm infection on its own will
not obviate the necessity for a restricted diet in CD. However, this
experimental human challenge system appears to be a safe way of
investigating the effect helminth parasites might impact on
immune pathology. The advantages are that it directly addresses
the human response, the disease process is not affected by the
clinical imperative to use immune modulating therapy, intestinal
tissue as well as blood is available for analyses and antigen
stimulation testing can be effected both in vivo and in vitro.
Figure 6. Histological and immunological results. (A) Marsh score and (B) IFN-c ELISpot. Data was analyzed by two-way ANOVA: significant
effects of time only were shown as indicated, no significant effect of group or interaction was found in (A) or (B).
doi:10.1371/journal.pone.0017366.g006
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